ATE522621T1 - Diagnose und behandlung von williams syndrom - Google Patents

Diagnose und behandlung von williams syndrom

Info

Publication number
ATE522621T1
ATE522621T1 AT05108543T AT05108543T ATE522621T1 AT E522621 T1 ATE522621 T1 AT E522621T1 AT 05108543 T AT05108543 T AT 05108543T AT 05108543 T AT05108543 T AT 05108543T AT E522621 T1 ATE522621 T1 AT E522621T1
Authority
AT
Austria
Prior art keywords
williams syndrome
elastin gene
elastin
diagnosis
gene
Prior art date
Application number
AT05108543T
Other languages
English (en)
Inventor
Mark T Keating
Mark F Leppert
Colleen A Morris
Original Assignee
Univ Utah Res Found
Nevada System Of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found, Nevada System Of Higher Education filed Critical Univ Utah Res Found
Application granted granted Critical
Publication of ATE522621T1 publication Critical patent/ATE522621T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Electrotherapy Devices (AREA)
AT05108543T 1993-04-05 1994-04-04 Diagnose und behandlung von williams syndrom ATE522621T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4157693A 1993-04-05 1993-04-05

Publications (1)

Publication Number Publication Date
ATE522621T1 true ATE522621T1 (de) 2011-09-15

Family

ID=21917264

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05108543T ATE522621T1 (de) 1993-04-05 1994-04-04 Diagnose und behandlung von williams syndrom
AT94913974T ATE312198T1 (de) 1993-04-05 1994-04-04 Diagnose und behandlung von supravalvular aortic stenosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT94913974T ATE312198T1 (de) 1993-04-05 1994-04-04 Diagnose und behandlung von supravalvular aortic stenosis

Country Status (7)

Country Link
US (2) US5840489A (de)
EP (2) EP0694080B1 (de)
JP (1) JPH08512198A (de)
AT (2) ATE522621T1 (de)
CA (1) CA2158479C (de)
DE (1) DE69434566T2 (de)
WO (1) WO1994023638A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858662A (en) * 1993-04-05 1999-01-12 University Of Utah Research Foundation Diagnosis of Williams syndrome and Williams syndrome cognitive profile by analysis of the presence or absence of a LIM-kinase gene
US5672500A (en) * 1995-05-18 1997-09-30 Thomas Jefferson University Mch2, an apoptotic cysteine protease, and compositions for making and methods of using the same
EP1064382B1 (de) 1998-03-17 2008-08-20 Genentech, Inc. Zu vegf und bmp1 homologe polypeptide
US6903244B1 (en) 1999-02-26 2005-06-07 University Of Utah Research Foundation Mice which are +/− or −/− for the elastin gene as models for vascular disease
AU772452B2 (en) * 1999-06-25 2004-04-29 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Nucleic acid binding of multi-zinc finger transcription factors
US20030079236A1 (en) * 1999-09-10 2003-04-24 Comings David E. Polymorphisms associated with internalizing disorders
WO2001025433A2 (en) * 1999-10-07 2001-04-12 Genentech, Inc. Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization
IL150987A0 (en) 2000-02-11 2003-02-12 Genentech Inc Novel inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization
US6395488B1 (en) * 2000-04-28 2002-05-28 City Of Hope Cholecystokinin (CCK) gene as a risk factor for smoking in women
EP2792747A1 (de) 2000-06-23 2014-10-22 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
EP2075253A1 (de) 2000-06-23 2009-07-01 Genentech, Inc. Methoden und Verbindungen zur Diagnose und Behandlung von Krankheiten, an denen Angiogenese beteiligt ist
US20050130149A1 (en) * 2001-10-25 2005-06-16 Osborne Lucy R. Method for williams-beuren syndrome diagnosis
AU2003228382A1 (en) * 2002-03-27 2003-10-13 University Of Utah Research Foundation Elastin prevents occlusion of body vessels by vascular smooth muscle cells
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
WO2004081186A2 (en) * 2003-03-10 2004-09-23 Applera Corporation Single nucleotide polymorphisms associated with stenosis, methods of detection and uses thereof
CA2566257A1 (en) * 2004-05-07 2005-11-24 Applera Corporation Genetic polymorphisms associated with vascular diseases, methods of detection and uses thereof
WO2006132788A2 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
EP1995321A2 (de) 2005-08-15 2008-11-26 Genentech, Inc. Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
WO2007081608A2 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
CA2638821A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
CA2649387A1 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto

Also Published As

Publication number Publication date
US5650282A (en) 1997-07-22
ATE312198T1 (de) 2005-12-15
WO1994023638A3 (en) 1994-12-08
US5840489A (en) 1998-11-24
DE69434566T2 (de) 2006-07-13
JPH08512198A (ja) 1996-12-24
EP0694080B1 (de) 2005-12-07
EP0694080A4 (de) 1998-08-05
DE69434566D1 (de) 2006-01-12
EP1612280B1 (de) 2011-08-31
EP1612280A2 (de) 2006-01-04
EP0694080A1 (de) 1996-01-31
EP1612280A3 (de) 2009-05-20
WO1994023638A2 (en) 1994-10-27
CA2158479C (en) 2009-07-07
CA2158479A1 (en) 1994-10-27

Similar Documents

Publication Publication Date Title
ATE312198T1 (de) Diagnose und behandlung von supravalvular aortic stenosis
Zald et al. Implications of the hierarchical structure of psychopathology for psychiatric neuroimaging
Bradshaw et al. Guillain–Barré syndrome in children: clinical course, electrodiagnosis, and prognosis
Shulman et al. The evolution of disability in Parkinson disease
Roar et al. Practice effect in Symbol Digit Modalities Test in multiple sclerosis patients treated with natalizumab
Aubin et al. Daily activities, cognition and community functioning in persons with schizophrenia
Kessing et al. Recurrence in affective disorder: analyses with frailty models
DE60325617D1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
Lee et al. Electroencephalographic features of patients with SCN1A-positive Dravet syndrome
Quijano‐Roy et al. EMG and nerve conduction studies in children with congenital muscular dystrophy
ATE427993T1 (de) EIN GEN DES ßLANGEN QT SYNDROMSß (LONG QT SYNDROM), WELCHES KVLQT1 KODIERT UND SEINE WECHSELWIRKUNG MIT MINK
Fromm et al. Oral health‐related quality of life, oral aesthetics and oral function in head and neck cancer patients after oral rehabilitation
Stephan et al. Neuropathological profile of mild cognitive impairment from a population perspective
Memel et al. Sex differences in the clinical manifestation of autosomal dominant frontotemporal dementia
DE69705936D1 (de) Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose
ATE261497T1 (de) Diagnostisches verfahren und gerät
Bromberg An approach to the evaluation of peripheral neuropathies
Claridge et al. Covariation between two-flash threshold and skin conductance level in first-breakdown schizophrenics: Relationships in drug-free patients and effects of treatment
Rassaby et al. Examining the relationship between pre-treatment anhedonia and treatment outcomes in individuals with anxiety or depression: a systematic review
RU2000122805A (ru) Способ оценки эффективности лечения ишемической болезни сердца
Kolata A blood test for alzheimer’s? it’s coming, scientists report
RU2002134058A (ru) Способ дифференциальной диагностики типа деменции
Eghbalieh et al. Prenatal stimulant exposure affects alerting and executive control in six and seven-year-olds
SE8701437D0 (sv) Diagnostiskt forfarande in vitro samt medel som kan utnyttjas vid forfarandet
ATE80465T1 (de) Diagnose von fettleibigkeit, hervorgerufen durch eine genetische abnormalitaet, und verfahren zur therapeutischen behandlung von genetisch bedingter fettleibigkeit.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties